Larimar Therapeutics’ (LRMR) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMRFree Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $25.00 target price on the stock.

Several other research analysts have also recently commented on the stock. Leerink Partnrs reiterated an outperform rating on shares of Larimar Therapeutics in a report on Wednesday, April 3rd. Lifesci Capital restated an outperform rating on shares of Larimar Therapeutics in a report on Tuesday, February 20th. SVB Leerink started coverage on shares of Larimar Therapeutics in a report on Wednesday, April 3rd. They issued an outperform rating and a $25.00 target price for the company. Finally, Citigroup upped their target price on shares of Larimar Therapeutics from $4.50 to $10.00 and gave the company a buy rating in a report on Tuesday, February 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of Buy and an average target price of $20.00.

Get Our Latest Analysis on LRMR

Larimar Therapeutics Stock Up 8.5 %

NASDAQ LRMR opened at $7.89 on Tuesday. Larimar Therapeutics has a 52 week low of $2.18 and a 52 week high of $13.68. The stock has a market capitalization of $503.40 million, a PE ratio of -8.13 and a beta of 0.96. The firm has a 50 day moving average of $7.47 and a two-hundred day moving average of $6.45.

Larimar Therapeutics (NASDAQ:LRMRGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts expect that Larimar Therapeutics will post -1.29 earnings per share for the current fiscal year.

Institutional Trading of Larimar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Pale Fire Capital SE purchased a new stake in Larimar Therapeutics in the 3rd quarter valued at $48,000. EntryPoint Capital LLC acquired a new position in shares of Larimar Therapeutics during the 1st quarter worth $106,000. SG Americas Securities LLC grew its stake in shares of Larimar Therapeutics by 27.3% during the 4th quarter. SG Americas Securities LLC now owns 14,159 shares of the company’s stock worth $64,000 after purchasing an additional 3,039 shares during the period. Virtu Financial LLC acquired a new position in shares of Larimar Therapeutics during the 1st quarter worth $133,000. Finally, Fred Alger Management LLC grew its stake in shares of Larimar Therapeutics by 22.5% during the 3rd quarter. Fred Alger Management LLC now owns 116,269 shares of the company’s stock worth $459,000 after purchasing an additional 21,331 shares during the period. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Featured Stories

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.